Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The active pharmaceutical ingredient (API) in Mounjaro, the weight-loss drug produced by Eli Lilly, is Ireland’s biggest ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

(RTTNews) - Eli Lilly And Co. (LLY) filed lawsuits Tuesday against Strive Pharmacy and Empower Pharmacy, accusing them of unlawfully compounding and selling tirzepatide, the active ingredient in ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...